Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) scored a legal victory when a district court ruled that its patent rights of its Eylea retinal-disease drug were infringed upon by rival Viatris Inc. (NASDAQ:VTRS).
Regeneron Gains After Eye-Drug Patent Victory Over Viatris bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Regeneron Gains After Eye-Drug Patent Victory Over Viatris yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma's patent tactics fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.